Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer | Zendy

Suresh S. Ramalingam | Zendy; David R. Spigel | Zendy; David Chen | Zendy; Martin Steins | Zendy; Jeffrey A. Engelman | Zendy; Claus-Peter Schneider | Zendy; Silvia Novello | Zendy; Wilfried Eberhardt | Zendy; Lucio Crinó | Zendy; Kai Habben | Zendy; Lian Liu | Zendy; Pasi A. Jänne | Zendy; Carrie Brownstein | Zendy; Martin Reck | Zendy

Open Access

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Author(s) -

Suresh S. Ramalingam,

David R. Spigel,

David Chen,

Martin Steins,

Jeffrey A. Engelman,

Claus-Peter Schneider,

Silvia Novello,

Wilfried Eberhardt,

Lucio Crinó,

Kai Habben,

Lian Liu,

Pasi A. Jänne,

Carrie Brownstein,

Martin Reck

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.36.6799

Subject(s) - medicine , erlotinib , placebo , hazard ratio , gastroenterology , clinical endpoint , lung cancer , epidermal growth factor receptor , phases of clinical research , oncology , cancer , surgery , randomized controlled trial , clinical trial , pathology , confidence interval , alternative medicine

R1507 is a selective, fully human, recombinant monoclonal antibody (immunoglobulin G1 subclass) against insulin-like growth factor-1 receptor (IGF-1R). The strong preclinical evidence supporting coinhibition of IGF-1R and epidermal growth factor receptor (EGFR) as anticancer therapy prompted this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research